Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Sci Rep ; 9(1): 6542, 2019 04 25.
Artículo en Inglés | MEDLINE | ID: mdl-31024069

RESUMEN

Research and therapeutic applications create a high demand for primary human hepatocytes. The limiting factor for their utilization is the availability of metabolically active hepatocytes in large quantities. Centrifugation through Percoll, which is commonly performed during hepatocyte isolation, has so far not been systematically evaluated in the scientific literature. 27 hepatocyte isolations were performed using a two-step perfusion technique on tissue obtained from partial liver resections. Cells were seeded with or without having undergone the centrifugation step through 25% Percoll. Cell yield, function, purity, viability and rate of bacterial contamination were assessed over a period of 6 days. Viable yield without Percoll purification was 42.4 × 106 (SEM ± 4.6 × 106) cells/g tissue. An average of 59% of cells were recovered after Percoll treatment. There were neither significant differences in the functional performance of cells, nor regarding presence of non-parenchymal liver cells. In five cases with initial viability of <80%, viability was significantly increased by Percoll purification (71.6 to 87.7%, p = 0.03). Considering our data and the massive cell loss due to Percoll purification, we suggest that this step can be omitted if the initial viability is high, whereas low viabilities can be improved by Percoll centrifugation.


Asunto(s)
Separación Celular/métodos , Hepatocitos/citología , Aspartato Aminotransferasas/genética , Aspartato Aminotransferasas/metabolismo , Supervivencia Celular/genética , Supervivencia Celular/fisiología , Células Cultivadas , Hepatectomía , Hepatocitos/metabolismo , Humanos , Povidona , Dióxido de Silicio
2.
Chirurg ; 90(9): 744-751, 2019 Sep.
Artículo en Alemán | MEDLINE | ID: mdl-30707248

RESUMEN

BACKGROUND: Liver transplantation is the only curative treatment option for patients with end-stage liver disease; however, the 40% decline of available organ donors in recent years in Germany necessitates the optimization of available resources and possibly extending the criteria to older donors. MATERIAL AND METHODS: All 2652 livers made available to the Charité Universitätsmedizin Berlin from 2010 to 2016 were retrospectively analyzed and the clinical outcome of 526 liver transplantations during this time frame were evaluated. RESULTS: The median age of donors of transplanted organs increased from 49.3 years in 2010 to 57.3 years in 2016 (p = 0.02). Organs from donors ≥65 years were more frequently discarded than organs from younger donors (n = 344, 18.4% vs. n = 220, 28.1%; p = 0.005). Moreover, the older donors had higher rates of diabetes mellitus and hepatic steatosis. Organs from older donors had a higher donor risk index (2.8 vs. 2.2; p < 0.001) and were transplanted more often in patients with preserved liver function and hepatocellular carcinoma and liver cirrhosis (n = 121, 74.7% of indications). The 3­year survival after liver transplantation from donors ≥65 and ≥80 years old was not significantly reduced in comparison to younger donors; however, there was an increased retransplantation rate (28.6%; p = 0.005) after transplantation of organs from donors ≥80 years old. CONCLUSION: Despite conservative organ acceptance there were higher rates of retransplantation after transplantation from very old donors. In the light of an increasing scarcity of suitable organs this mandates caution and highlights the need for adequate assessment instruments for marginal donor organs before transplantation.


Asunto(s)
Factores de Edad , Neoplasias Hepáticas , Trasplante de Hígado , Donantes de Tejidos , Anciano de 80 o más Años , Berlin , Alemania , Supervivencia de Injerto , Humanos , Persona de Mediana Edad , Estudios Retrospectivos , Resultado del Tratamiento
3.
Cell Transplant ; 28(1_suppl): 14S-24S, 2019 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-31842585

RESUMEN

Hepatocyte transplantation (HcTx) is a promising approach for the treatment of metabolic diseases in newborns and children. The most common application route is the portal vein, which is difficult to access in the newborn. Transfemoral access to the splenic artery for HcTx has been evaluated in adults, with trials suggesting hepatocyte translocation from the spleen to the liver with a reduced risk for thromboembolic complications. Using juvenile Göttingen minipigs, we aimed to evaluate feasibility of hepatocyte transplantation by transfemoral splenic artery catheterization, while providing insight on engraftment, translocation, viability, and thromboembolic complications. Four Göttingen Minipigs weighing 5.6 kg to 12.6 kg were infused with human hepatocytes (two infusions per cycle, 1.00E08 cells per kg body weight). Immunosuppression consisted of tacrolimus and prednisolone. The animals were sacrificed directly after cell infusion (n=2), 2 days (n=1), or 14 days after infusion (n=1). The splenic and portal venous blood flow was controlled via color-coded Doppler sonography. Computed tomography was performed on days 6 and 18 after the first infusion. Tissue samples were stained in search of human hepatocytes. Catheter placement was feasible in all cases without procedure-associated complications. Repetitive cell transplantations were possible without serious adverse effects associated with hepatocyte transplantation. Immunohistochemical staining has proven cell relocation to the portal venous system and liver parenchyma. However, cells were neither present in the liver nor the spleen 18 days after HcTx. Immunological analyses showed a response of the adaptive immune system to the human cells. We show that interventional cell application via the femoral artery is feasible in a juvenile large animal model of HcTx. Moreover, cells are able to pass through the spleen to relocate in the liver after splenic artery infusion. Further studies are necessary to compare this approach with umbilical or transhepatic hepatocyte administration.


Asunto(s)
Hepatocitos/trasplante , Hígado/citología , Arteria Esplénica , Animales , Cateterismo/métodos , Trasplante de Células/efectos adversos , Trasplante de Células/métodos , Hepatocitos/citología , Hepatocitos/enzimología , Hepatocitos/inmunología , Humanos , Terapia de Inmunosupresión , Hígado/enzimología , Hígado/patología , Modelos Animales , Vena Porta/citología , Bazo/citología , Bazo/diagnóstico por imagen , Bazo/patología , Arteria Esplénica/citología , Porcinos , Porcinos Enanos , Factores de Tiempo , Tomografía Computarizada por Rayos X , Ultrasonografía Doppler
4.
Int J Artif Organs ; 31(3): 252-7, 2008 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-18373319

RESUMEN

The transplantation of primary human hepatocytes is a promising approach in the treatment of specific liver diseases. However, little is known about the fate of the cells following application. Magnetic resonance imaging (MRI) could enable real-time tracking and long-term detection of transplanted hepatocytes. The use of superparamagnetic iron oxide particles as cellular contrast agents should allow for the non-invasive detection of labelled cells on high-resolution magnetic resonance images. Experiments were performed on primary human hepatocytes to transfer the method of detecting labelled cells via clinical MRI into human hepatocyte transplantation. For labelling, Tat-peptide modified nano-sized superparamagnetic MagForce particles were used. Cells were investigated via a clinical MR scanner at 3.0 Tesla and the particle uptake within single hepatocytes was estimated using microscopic examinations. The labelled primary human hepatocytes were clearly detectable by MRI, proving the feasibility of this new concept. Therefore, this method is a useful tool to investigate the effects of human hepatocyte transplantation and to improve safety aspects of this method.


Asunto(s)
Productos del Gen tat/química , Hepatocitos/trasplante , Nanopartículas del Metal/uso terapéutico , Células Cultivadas , Estudios de Factibilidad , Compuestos Férricos , Humanos , Imagen por Resonancia Magnética , Nanotecnología , Tamaño de la Partícula
5.
Eur J Surg Oncol ; 43(9): 1668-1681, 2017 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-28599872

RESUMEN

Patients with colorectal liver metastases (CLM) have remarkably benefited from the advances in medical multimodal treatment and surgical techniques over the last two decades leading to significant improvements in long-term survival. More patients are currently undergoing liver resection following neoadjuvant chemotherapy, which has been increasingly established within the framework of curative-indented treatment strategies. However, the use of several cytotoxic agents has been linked to specific liver injuries that not only impair the ability of liver tissue to regenerate but also decrease long-term survival. One of the most common agents included in modern chemotherapy regimens is oxaliplatin, which is considered to induce a parenchymal damage of the liver primarily involving the sinusoids defined as sinusoidal obstruction syndrome (SOS). Administration of bevacizumab, an inhibitor of vascular endothelial growth factor (VEGF), has been reported to improve response of CLM to chemotherapy in clinical studies, concomitantly protecting the liver from the development of SOS. In this review, we aim to summarize current data on multimodal treatment concepts for CLM, give an in-depth overview of liver damage caused by cytostatic agents focusing on oxaliplatin-induced SOS, and evaluate the role of bevacizumab to improve clinical outcomes of patients with CLM and to protect the liver from the development of SOS.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Bevacizumab/administración & dosificación , Neoplasias Colorrectales/patología , Enfermedad Veno-Oclusiva Hepática/inducido químicamente , Neoplasias Hepáticas/tratamiento farmacológico , Compuestos Organoplatinos/efectos adversos , Camptotecina/administración & dosificación , Camptotecina/efectos adversos , Camptotecina/análogos & derivados , Cetuximab/administración & dosificación , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Fluorouracilo/administración & dosificación , Fluorouracilo/efectos adversos , Hepatectomía , Enfermedad Veno-Oclusiva Hepática/prevención & control , Humanos , Irinotecán , Neoplasias Hepáticas/secundario , Neoplasias Hepáticas/cirugía , Terapia Neoadyuvante , Compuestos Organoplatinos/administración & dosificación , Oxaliplatino , Tasa de Supervivencia
6.
Sci Rep ; 7: 41777, 2017 02 02.
Artículo en Inglés | MEDLINE | ID: mdl-28150744

RESUMEN

Decellularization of pancreata and repopulation of these non-immunogenic matrices with islets and endothelial cells could provide transplantable, endocrine Neo- Pancreata. In this study, rat pancreata were perfusion decellularized and repopulated with intact islets, comparing three perfusion routes (Artery, Portal Vein, Pancreatic Duct). Decellularization effectively removed all cellular components but conserved the pancreas specific extracellular matrix. Digital subtraction angiography of the matrices showed a conserved integrity of the decellularized vascular system but a contrast emersion into the parenchyma via the decellularized pancreatic duct. Islets infused via the pancreatic duct leaked from the ductular system into the peri-ductular decellularized space despite their magnitude. TUNEL staining and Glucose stimulated insulin secretion revealed that islets were viable and functional after the process. We present the first available protocol for perfusion decellularization of rat pancreata via three different perfusion routes. Furthermore, we provide first proof-of-concept for the repopulation of the decellularized rat pancreata with functional islets of Langerhans. The presented technique can serve as a bioengineering platform to generate implantable and functional endocrine Neo-Pancreata.


Asunto(s)
Bioingeniería , Islotes Pancreáticos/fisiología , Regeneración , Andamios del Tejido , Animales , Biomarcadores , Supervivencia Celular , Matriz Extracelular , Femenino , Supervivencia de Injerto , Inmunohistoquímica , Islotes Pancreáticos/citología , Islotes Pancreáticos/ultraestructura , Masculino , Ratas
7.
Lab Anim ; 51(4): 388-396, 2017 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-27932686

RESUMEN

Over the past 50 years, image-guided procedures have been established for a wide range of applications. The development and clinical translation of new treatment regimens necessitate the availability of suitable animal models. The juvenile Göttingen minipig presents a favourable profile as a model for human infants. However, no information can be found regarding the vascular system of juvenile minipigs in the literature. Such information is imperative for planning the accessibility of target structures by catheterization. We present here a complete mapping of the arterial system of the juvenile minipig based on contrast-enhanced computed tomography. Four female animals weighing 6.13 ± 0.72 kg were used for the analyses. Imaging was performed under anaesthesia, and the measurement of the vascular structures was performed independently by four investigators. Our dataset forms a basis for future interventional studies in juvenile minipigs, and enables planning and refinement of future experiments according to the 3R (replacement, reduction and refinement) principles of animal research.


Asunto(s)
Vasos Sanguíneos/anatomía & histología , Porcinos Enanos/anatomía & histología , Tomografía Computarizada por Rayos X , Animales , Femenino , Humanos , Modelos Animales , Flujo Sanguíneo Regional , Encuestas y Cuestionarios , Porcinos
8.
Eur J Endocrinol ; 169(5): 547-57, 2013 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-23935128

RESUMEN

OBJECTIVE: Adipose tissue-derived factors link non-alcoholic fatty liver disease (NAFLD) with obesity, which has also been reported for circulating chemerin. On the other hand, hepatic chemerin and chemokine-like receptor 1 (CMKLR1) mRNA expression has not yet been studied in an extensively characterized patient collective. DESIGN: This study was cross-sectional and experimental in design. METHODS: Liver tissue samples were harvested from 47 subjects and histologically examined according to the NAFLD activity score (NAS). The concentrations of chemerin and CMKLR1 were measured using semi-quantitative real-time PCR, and the concentration of serum chemerin was measured using ELISA. To evaluate potential effects of chemerin and CMKLR1, cultured primary human hepatocytes (PHHs) were exposed to selected metabolites known to play a role in NAFLD (insulin, glucagon, palmitoic acid, and interleukin-6 (IL6)). RESULTS: Chemerin and CMKLR1 mRNA levels were elevated in the human liver. Their expression was correlated with the NAS (R(2)=0.543; P<0.001 and R(2)=0.355; P=0.014 respectively) and was significantly elevated in patients with definite non-alcoholic steatohepatitis (NASH) (P<0.05 respectively). Linear regression analysis confirmed an independent association of liver fibrosis, steatosis, inflammation, and hepatocyte ballooning with hepatic chemerin mRNA expression (P<0.05 respectively). The expression of hepatic chemerin and CMKLR1 was correlated with the measures of obesity (P<0.05). The incubation of PHHs with IL6 significantly increased the expression of CMKLR1 mRNA (P=0.027), while that of chemerin remained unaffected (P>0.05). None of the other metabolites showed an influence (P>0.05). CONCLUSION: This is the first study to show that chemerin mRNA expression is significantly elevated in the liver of NASH patients and that CMKLR1 expression is upregulated in liver inflammation, whereby IL6 could play a causal role.


Asunto(s)
Quimiocinas/biosíntesis , Hígado Graso/metabolismo , Hígado/metabolismo , ARN Mensajero/biosíntesis , Anciano , Peso Corporal/fisiología , Células Cultivadas , Quimiocinas/genética , Estudios Transversales , Hígado Graso/patología , Femenino , Humanos , Péptidos y Proteínas de Señalización Intercelular , Modelos Lineales , Hígado/patología , Cirrosis Hepática/patología , Masculino , Persona de Mediana Edad , Enfermedad del Hígado Graso no Alcohólico , ARN Mensajero/genética , Reacción en Cadena en Tiempo Real de la Polimerasa , Receptores de Quimiocina/biosíntesis , Receptores de Quimiocina/genética
9.
Transplant Proc ; 44(4): 999-1001, 2012 May.
Artículo en Inglés | MEDLINE | ID: mdl-22564608

RESUMEN

Diseased human organs explanted during liver transplantation can be used as a cell source for basic research and future therapeutic applications in regenerative medicine. Enzymatic digestion using the perfusion technique has become the gold standard in liver cell isolation. Usually the portal vein is used as a vascular access for liver cell isolation from explanted livers, that were rejected from whole organ transplantation. No special techniques are required for cannulation; the cannulas are simply introduced into the vessels and a ligature is then thrown around the vessel to secure the cannulation. This method is not applicable to organs explanted during liver transplant surgery, because as much of the vessels as possible has to be kept in situ, to facilitate anastomosis of the new organ. Therefore, when perfusing the explanted organ, normal perfusion catheters are easily displaced and a more complex "vascular reconstruction" must be performed to secure hold of the catheters. We established a novel cannulation technique using commercially available Foley catheters for liver cell isolation from diseased whole organs explanted during transplant surgery. We evaluated this technique in 15 diseased organs. 5 were isolated in the conventional setting and 10 were cannulated using Foley catheters. The average cannulation time was significantly shortened using Foley catheters compared with the conventional approach (12 ± 5.2 min vs 40 ± 14.1 min; P = .0001). Foley catheter cannulation is fast, simple, and efficient. It appears to be favorable for hepatocyte isolation from diseased whole livers or from explanted organs with technically difficult vascular access.


Asunto(s)
Cateterismo , Separación Celular/métodos , Hepatectomía , Hepatocitos/patología , Hígado/cirugía , Perfusión , Cateterismo/instrumentación , Catéteres , Separación Celular/instrumentación , Diseño de Equipo , Humanos , Hígado/irrigación sanguínea , Hígado/patología , Perfusión/instrumentación , Vena Porta
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA